메뉴 건너뛰기




Volumn 45, Issue 4, 2011, Pages 285-291

Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer-a single institution retrospective analysis

Author keywords

BRAF; KRAS; metastatic colorectal cancer; prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GLUTAMIC ACID; IRINOTECAN; K RAS PROTEIN; MONOCLONAL ANTIBODY; OXALIPLATIN; VALINE;

EID: 81755161614     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/v10019-011-0039-y     Document Type: Article
Times cited : (11)

References (37)
  • 2
    • 13744251436 scopus 로고    scopus 로고
    • Systemic therapy for colorectal cancer
    • Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl Med 2005; 352: 476-87.
    • (2005) N Engl Med , vol.352 , pp. 476-487
    • Meyerhardt, J.A.1    Mayer, R.J.2
  • 3
    • 58149147003 scopus 로고    scopus 로고
    • Quality of life in patients after combined modality treatment of rectal cancer: Report of a prospective phase II study
    • Velenik V, Oblak I, Anderluh F. Quality of life in patients after combined modality treatment of rectal cancer: Report of a prospective phase II study. Radiol Oncol 2008; 42: 207-14.
    • (2008) Radiol Oncol , vol.42 , pp. 207-214
    • Velenik, V.1    Oblak, I.2    Anderluh, F.3
  • 4
    • 77958181103 scopus 로고    scopus 로고
    • Post-treatment surveillance in colorectal cancer
    • Velenik V. Post-treatment surveillance in colorectal cancer. Radiol Oncol 2010; 44: 135-41
    • (2010) Radiol Oncol , vol.44 , pp. 135-141
    • Velenik, V.1
  • 6
    • 77954346705 scopus 로고    scopus 로고
    • Advanced colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment
    • Advanced colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment. Ann Oncol 2010; 21: v93-7.
    • (2010) Ann Oncol , vol.21
  • 7
    • 78649401745 scopus 로고    scopus 로고
    • How to integrate molecular targeted agents in the continuum of care
    • Kohne CH. How to integrate molecular targeted agents in the continuum of care. Ann Oncol 2010; 21: vii134-9.
    • (2010) Ann Oncol , vol.21
    • Kohne, C.H.1
  • 8
    • 62949184214 scopus 로고    scopus 로고
    • Advances in the treatment of metastatic colorectal carcinoma
    • Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8.
    • (2009) Radiol Oncol , vol.43 , pp. 1-8
    • Ocvirk, J.1
  • 9
    • 23944469938 scopus 로고    scopus 로고
    • Targeting signal transduction pathways in colorectal cancer - More than skin deep
    • DOI 10.1200/JCO.2005.02.194
    • Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transducting pathways in colorectal cancer-More than skin deep. J Clin Oncol 2005; 23: 5374-85. (Pubitemid 46206991)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.23 , pp. 5374-5385
    • Cohen, S.J.1    Cohen, R.B.2    Meropol, N.J.3
  • 10
    • 72449176846 scopus 로고    scopus 로고
    • Molecular basis of colorectal cancer
    • Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60.
    • (2009) N Engl J Med , vol.361 , pp. 2449-2460
    • Markowitz, S.D.1    Bertagnolli, M.M.2
  • 12
  • 13
    • 77950398199 scopus 로고    scopus 로고
    • KRAS mutations in Slovene patients with colorectal cancer: Frequency, distribution and correlation with the response to treatment
    • Licar A, Cerkovnik P, Ocvirk J, Novakovic S. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. Int J Oncol 2010, 36: 1137-44.
    • (2010) Int J Oncol , vol.36 , pp. 1137-1144
    • Licar, A.1    Cerkovnik, P.2    Ocvirk, J.3    Novakovic, S.4
  • 14
    • 78049341541 scopus 로고    scopus 로고
    • Association of KRAS p.G13D mutation with outcome in patients with outcome with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    • De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with outcome with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-20.
    • (2010) JAMA , vol.304 , pp. 1812-1820
    • De Roock, W.1    Jonker, D.J.2    Di Nicolantonio, F.3    Sartore-Bianchi, A.4    Tu, D.5    Siena, S.6
  • 15
    • 42649145667 scopus 로고    scopus 로고
    • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
    • (2008) J Clin Oncol , vol.26 , pp. 1626-1634
    • Amado, R.G.1    Wolf, M.2    Peeters, M.3    Van Cutsem, E.4    Siena, S.5    Freeman, D.J.6
  • 16
    • 75749102647 scopus 로고    scopus 로고
    • Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
    • Roth AD, Tejpar S, Dolorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28:466-74.
    • (2010) J Clin Oncol , vol.28 , pp. 466-474
    • Roth, A.D.1    Tejpar, S.2    Dolorenzi, M.3    Yan, P.4    Fiocca, R.5    Klingbiel, D.6
  • 17
    • 63849316277 scopus 로고    scopus 로고
    • The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mCRC receiving first-line treatment with cetuximab or cetuximab plus folfiri. [Abstract]
    • Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Kohne C, et al. The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mCRC receiving first-line treatment with cetuximab or cetuximab plus folfiri. [Abstract]. Ann Oncol 2008; 19(Suppl 6): vi17-8.
    • (2008) Ann Oncol , vol.19 , Issue.SUPPL. 6
    • Van Cutsem, E.1    Lang, I.2    D'Haens, G.3    Moiseyenko, V.4    Zaluski, J.5    Kohne, C.6
  • 18
    • 67649652208 scopus 로고    scopus 로고
    • BRAF mutation in metastatic colorectal cancer
    • Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-99.
    • (2009) N Engl J Med , vol.361 , pp. 98-99
    • Tol, J.1    Nagtegaal, I.D.2    Punt, C.J.A.3
  • 19
    • 84655166465 scopus 로고    scopus 로고
    • Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer
    • Jul [Epub ahead of print]
    • Licar A, Cerkovnik P, Novakovic S. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Med Oncol 2010 Jul 20. [Epub ahead of print]
    • (2010) Med Oncol , vol.20
    • Licar, A.1    Cerkovnik, P.2    Novakovic, S.3
  • 20
    • 77955277111 scopus 로고    scopus 로고
    • Effect of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
    • De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effect of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
    • (2010) Lancet Oncol , vol.11 , pp. 753-762
    • De Roock, W.1    Claes, B.2    Bernasconi, D.3    De Schutter, J.4    Biesmans, B.5    Fountzilas, G.6
  • 21
    • 77949541470 scopus 로고    scopus 로고
    • PIK13CA BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): Results of a European Consortium
    • Tejpar S, De Roock W. PIK13CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated With EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium. Eur J Cancer 2009; 7: 322.
    • (2009) Eur J Cancer , vol.7 , pp. 322
    • Tejpar, S.1    De Roock, W.2
  • 22
    • 72449185665 scopus 로고    scopus 로고
    • The role of KRAS, BRAF, NRAS and PIK3CA mutations as a marker of resistence of cetuximab in chemorefractory metastatic colorectal cancer. [abstract]
    • Lambrechts D, De Roock W, Prenen H, De Schutter J, Jacobs B, Biesmans B, et al. The role of KRAS, BRAF, NRAS and PIK3CA mutations as a marker of resistence of cetuximab in chemorefractory metastatic colorectal cancer. [abstract] J Clin Oncol 2009; 27 (Suppl): 172.
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. , pp. 172
    • Lambrechts, D.1    De Roock, W.2    Prenen, H.3    De Schutter, J.4    Jacobs, B.5    Biesmans, B.6
  • 23
    • 78649473910 scopus 로고    scopus 로고
    • The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
    • Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21: 2396-2402.
    • (2010) Ann Oncol , vol.21 , pp. 2396-2402
    • Fariña-Sarasqueta, A.1    Van Lijnschoten, G.2    Moerland, E.3    Creemers, G.J.4    Lemmens, V.E.5    Rutten, H.J.6
  • 25
    • 84927971974 scopus 로고    scopus 로고
    • Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: A meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status
    • [abstract 406]
    • Kohne CH, Rougier P, Stroh C, Schlichting M, Bokemeyer C, Van Cutsem E, et al. Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: A meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. ASCO GI 2010 [abstract 406].
    • (2010) ASCO GI
    • Kohne, C.H.1    Rougier, P.2    Stroh, C.3    Schlichting, M.4    Bokemeyer, C.5    Van Cutsem, E.6
  • 26
    • 78649739337 scopus 로고    scopus 로고
    • Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status [abstract]
    • Bookemeyer C, Kohne CH, Rougier P, Stroh C, Schlichting M, Van Cutsem E, et al. Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status [abstract]. J Clin Oncol 2010; 28 (Suppl): 3506.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. , pp. 3506
    • Bookemeyer, C.1    Kohne, C.H.2    Rougier, P.3    Stroh, C.4    Schlichting, M.5    Van Cutsem, E.6
  • 27
    • 79960892233 scopus 로고    scopus 로고
    • Influence of KRAS G13D mutations on outcome in patients with meta-static colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab
    • [abstract 3511]
    • Tejpar S, Bukemeyer C, Celik I, Schlichting M, Sartorius U, Van Cutsem E, et al. Influence of KRAS G13D mutations on outcome in patients with meta-static colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. ASCO 2011 [abstract 3511].
    • (2011) ASCO
    • Tejpar, S.1    Bukemeyer, C.2    Celik, I.3    Schlichting, M.4    Sartorius, U.5    Van Cutsem, E.6
  • 28
    • 68749119351 scopus 로고    scopus 로고
    • KRAS codon 61, 146 and BRAF mutations predict resistence to cetuximab + irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
    • Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistence to cetuximab + irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-21.
    • (2009) Br J Cancer , vol.101 , pp. 715-721
    • Loupakis, F.1    Ruzzo, A.2    Cremolini, C.3    Vincenzi, B.4    Salvatore, L.5    Santini, D.6
  • 29
    • 76949093606 scopus 로고    scopus 로고
    • Activating K-ras mutations outwith 'hotspot' codons in sporadic colorectal tumours-implications for personalised cancer medicine
    • Smith G, Bounds R, Wolf H, Steele RJ, Carey FA, Wolf CR, et al. Activating K-ras mutations outwith 'hotspot' codons in sporadic colorectal tumours-implications for personalised cancer medicine. Br J Cancer 2010; 102: 1-11.
    • (2010) Br J Cancer , vol.102 , pp. 1-11
    • Smith, G.1    Bounds, R.2    Wolf, H.3    Steele, R.J.4    Carey, F.A.5    Wolf, C.R.6
  • 30
    • 70349690209 scopus 로고    scopus 로고
    • Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
    • Okines A, Del Puerto O, Cunningham D, Chau I, Van Cutsem E, Saltz L, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101: 1033-8.
    • (2009) Br J Cancer , vol.101 , pp. 1033-1038
    • Okines, A.1    Del Puerto, O.2    Cunningham, D.3    Chau, I.4    Van Cutsem, E.5    Saltz, L.6
  • 31
    • 79958115299 scopus 로고    scopus 로고
    • Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: Results of the ETNA cohort study (abstract 3594)
    • Terrebonne E, Smith D, Becouarn Y, Michel P, Guimbaud M, Fourrier-Reglat A, et al. Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: results of the ETNA cohort study (abstract 3594). J Clin Oncol 2010; 28: (Suppl.):15s.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL.
    • Terrebonne, E.1    Smith, D.2    Becouarn, Y.3    Michel, P.4    Guimbaud, M.5    Fourrier-Reglat, A.6
  • 32
    • 79958135377 scopus 로고    scopus 로고
    • Bevacizumab in first-line therapy of meta-static colorectal cancer: A retrospective comparison of FOLFIRI and XELIRI
    • Ocvirk J, Rebersek M, Boc M. Bevacizumab in first-line therapy of meta-static colorectal cancer: A retrospective comparison of FOLFIRI and XELIRI. Anticancer Res 2011; 31: 1777-82.
    • (2011) Anticancer Res , vol.31 , pp. 1777-1782
    • Ocvirk, J.1    Rebersek, M.2    Boc, M.3
  • 33
    • 79959947067 scopus 로고    scopus 로고
    • A multicentric study of capecit-abine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
    • Wong R, Cunningham D, Barbachano Y, et al. A multicentric study of capecit-abine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011; 22: 2042-8.
    • (2011) Ann Oncol , vol.22 , pp. 2042-2048
    • Wong, R.1    Cunningham, D.2    Barbachano, Y.3
  • 35
    • 59949091448 scopus 로고    scopus 로고
    • Fluorouracil, leucovorin, and oxaliplatin with or without cetuximab in the first-line treatment of metastatic colorectal cancer
    • Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with or without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-71.
    • (2009) J Clin Oncol , vol.27 , pp. 663-671
    • Bokemeyer, C.1    Bondarenko, I.2    Makhson, A.3    Hartmann, J.T.4    Aparicio, J.5    De Braud, F.6
  • 36
    • 73249130298 scopus 로고    scopus 로고
    • Tumour response and secondary resectability of colorectal liver me-tastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial
    • Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver me-tastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 1: 38-47.
    • (2010) Lancet Oncol , vol.1 , pp. 38-47
    • Folprecht, G.1    Gruenberger, T.2    Bechstein, W.O.3    Raab, H.R.4    Lordick, F.5    Hartmann, J.T.6
  • 37
    • 78149469673 scopus 로고    scopus 로고
    • Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
    • Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010; 103: 1-6.
    • (2010) Br J Cancer , vol.103 , pp. 1-6
    • Garufi, C.1    Torsello, A.2    Tumolo, S.3    Ettorre, G.M.4    Zeuli, M.5    Campanella, C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.